oral glp-1 drugs in development of an orally delivered receptor agonist through peptide engineering and drug delivery to treat chronic disease Comparing Ozempic, Wegovy and Other

These medications: Decrease pro-inflammatory cytokines including TNF-, IL-6, and IL-1 9 Reduce macrophage infiltration in tissues 40 Block NF-B activation, a key inflammation controller 41 Switch macrophages from pro-inflammatory M1 to anti-inflammatory M2 type 40 These effects show promise for various joint conditions

Paul Holmes Director of Science and Innovation at Naturecan Testing for large pharmaceutical & tobacco companies, Paul has built a wealth of scientific and regulatory knowledge, working on regulatory submissions to bodies such as the FDA and the MHRA

Check your formulary before signing up

Endocr Connect 2017;6:856-65.ArticlePubMedPMC 30

How about Tirzepatide